Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Jan 30, 2023 4:59pm
212 Views
Post# 35254902

RE:RE:RE:RE:SP

RE:RE:RE:RE:SPThe fact that ONC announced great data Nov regarding pancreatic cancer results, is certainly not worthless information.
However people using Ad Hominem attacks is not only worthless. In your case obvious.
The understanding that we have heard zero updates in over 30 days is due to negotiations.
key word " understanding" ...No knowledge, other than published dates & original contract.
Bracelet, was contractually approved by both Onc & Pfizer, before the trial was announced.
We know that part. It's also been calculated based on FDA & Onc reported enrolments, where they are in the trial.
so: from all of that, a reasonable expectation they are working on a deal.
great week all
BTW, previous posts on T.A. The numbers looked to break $ 2.08 on Nas. It reached $2.00 & fizzled.
This week. Only Monday..
regardless the big payout will be from an announcement with partner or buyout.
mean time traders will trade up & down.

<< Previous
Bullboard Posts
Next >>